<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02990403</url>
  </required_header>
  <id_info>
    <org_study_id>ShanghaiFMIH-0003</org_study_id>
    <nct_id>NCT02990403</nct_id>
  </id_info>
  <brief_title>The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss</brief_title>
  <official_title>The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai First Maternity and Infant Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai First Maternity and Infant Hospital</source>
  <brief_summary>
    <textblock>
      In this clinical cohort study, the investigators are going to observe the efficacy of
      anti-coagulation and immune therapy in the treatment of recurrent pregnancy loss with a
      prospective randomized controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 22, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>live birth</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>live birth means success pregnancy（more than gestational age of 20 weeks）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine artery blood flow</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>human chorionic gonadotropin</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Recurrent Pregnancy Loss</condition>
  <arm_group>
    <arm_group_label>aspirin+LMWH group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100U,hypodermic injection，qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin+LMWH+immunoglobulin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin+LMWH+prednisone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + prednisone,5-10mg/day,po,qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin+LMWH+IVIG+prednisone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks + prednisone,5-10mg/day,po,qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dydrogesterone group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>dydrogesterone 20-30mg/day, po, tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>aspirin+LMWH group</arm_group_label>
    <arm_group_label>aspirin+LMWH+immunoglobulin group</arm_group_label>
    <arm_group_label>aspirin+LMWH+prednisone group</arm_group_label>
    <arm_group_label>aspirin+LMWH+IVIG+prednisone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <arm_group_label>aspirin+LMWH group</arm_group_label>
    <arm_group_label>aspirin+LMWH+immunoglobulin group</arm_group_label>
    <arm_group_label>aspirin+LMWH+prednisone group</arm_group_label>
    <arm_group_label>aspirin+LMWH+IVIG+prednisone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>aspirin+LMWH+prednisone group</arm_group_label>
    <arm_group_label>aspirin+LMWH+IVIG+prednisone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunoglobulin</intervention_name>
    <arm_group_label>aspirin+LMWH+immunoglobulin group</arm_group_label>
    <arm_group_label>aspirin+LMWH+IVIG+prednisone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone</intervention_name>
    <arm_group_label>dydrogesterone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Woman who had 2 miscarriage before 12(th) week of gestation.The patient who is diagnosed
        as thrombophilia with recurrent pregnancy loss. Signed consent form.

        Exclusion Criteria:

          1. having experienced severe allergies, trauma history and/or operation history within 3
             months.

          2. with a history of mental illness and/or family history of mental illness limb
             disabled.

          3. taking medicine within one month.

          4. suffering major events or having mood swings.

          5. having internal and surgical disease(after having variety of physical examination such
             as electrocardiogram/hepatic and renal function/blood routine and urine routine)

          6. chromosome aberrations in anyone of the couple.

          7. patients who have drugs contraindications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai first Maternity and Infant health hospital, Tong Ji University</name>
      <address>
        <city>Shanghai</city>
        <zip>200051</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shihua Bao, PhD</last_name>
      <phone>86-21-20261430</phone>
      <phone_ext>2012</phone_ext>
      <email>baoshihua@tongji.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yan Yan, Master</last_name>
      <phone>86-21-20261430</phone>
      <phone_ext>2012</phone_ext>
      <email>shtjyanyan@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shihua Chen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan Yan, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai First Maternity and Infant Hospital</investigator_affiliation>
    <investigator_full_name>Shihua Bao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Fetal Death</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

